Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HMGCR | P04035 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | ACLY | P53396 | 3/20 | 0.42 |
| ▸ | CPT2 | P23786 | 1/20 | 0.41 |
| ▸ | TET2 | Q6N021 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL7921329 | 0.73 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL6878945 | 0.73 | — | — | |
| Citric Acid SCHEMBL28304336 | 0.71 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL28544352 | 0.71 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL952444 | 0.71 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL27500370 | 0.71 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL8777502 | 0.71 | — | — | |
| Citric Acid SCHEMBL2034627 | 0.71 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL1045797 | 0.71 | — | — | |
| Citric Acid SCHEMBL1332229 | 0.69 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1434761-B1 | SALTS OF GUANIDINE DERIVATIVES AND PHARMACEUTICAL PREPARATIONS CONSISTING THEREOF | BIOSPHINGS AG (DE) | 2010-02-24 | — | — | EP | claimed |
| CN-100488946-C | Salts of guanidine derivatives and its pharmaceutical preparations composition | BIOSPHINGS AG (DE) | 2009-05-20 | — | — | CN | claimed |
| US-7078566-B2 | Salts of guanidine derivatives and pharmaceutical preparations consisting thereof | BIOSPHINKS AKTIENGESELLSCHAFT (DE) | 2006-07-18 | — | — | US | claimed |
| CN-1568308-A | Salts of guanidine derivatives and pharmaceutical preparations consisting thereof | BIOSPHINGS AG (DE) | 2005-01-19 | — | — | CN | claimed |
| US-20040192717-A1 | Salts of guanidine derivatives and pharmaceutical preparations consisting thereof | BIOSPHINGS AKTIENGESELLSCHAFT (DE) | 2004-09-30 | — | — | US | claimed |
| CN-100488946-C | Salts of guanidine derivatives and its pharmaceutical preparations composition | BIOSPHINGS AG (DE) | 2009-05-20 | — | — | CN | disclosed |
| US-7078566-B2 | Salts of guanidine derivatives and pharmaceutical preparations consisting thereof | BIOSPHINKS AKTIENGESELLSCHAFT (DE) | 2006-07-18 | — | — | US | disclosed |
| CN-1568308-A | Salts of guanidine derivatives and pharmaceutical preparations consisting thereof | BIOSPHINGS AG (DE) | 2005-01-19 | — | — | CN | disclosed |
| US-20040192717-A1 | Salts of guanidine derivatives and pharmaceutical preparations consisting thereof | BIOSPHINGS AKTIENGESELLSCHAFT (DE) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192717-A1 | Salts of guanidine derivatives and pharmaceutical preparations consisting thereof | ODC1, GANC, AOC2 | ALDH1A1 4109/4885HMGCR 1174/4885CHRM1 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.